135 related articles for article (PubMed ID: 22882727)
1. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.
Jiang XY; Zhang Q; Chen P; Li SY; Zhang NN; Chen XD; Wang GC; Wang HB; Zhuang MQ; Lu M
J Clin Pharm Ther; 2012 Dec; 37(6):719-23. PubMed ID: 22882727
[TBL] [Abstract][Full Text] [Related]
2. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin.
Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
Atherosclerosis; 2004 Aug; 175(2):287-93. PubMed ID: 15262185
[TBL] [Abstract][Full Text] [Related]
3. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin.
Wei KK; Zhang LR; Zhang Y; Hu XJ
J Clin Pharm Ther; 2011 Dec; 36(6):725-33. PubMed ID: 21128988
[TBL] [Abstract][Full Text] [Related]
4. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
5. A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.
Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
Atherosclerosis; 2005 Jun; 180(2):407-15. PubMed ID: 15910869
[TBL] [Abstract][Full Text] [Related]
6. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.
Kadam P; Ashavaid TF; Ponde CK; Rajani RM
J Clin Pharm Ther; 2016 Jun; 41(3):329-33. PubMed ID: 26932749
[TBL] [Abstract][Full Text] [Related]
7. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin.
Kajinami K; Brousseau ME; Nartsupha C; Ordovas JM; Schaefer EJ
J Lipid Res; 2004 Apr; 45(4):653-6. PubMed ID: 14703505
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice.
Fu ZD; Cui JY; Klaassen CD
J Lipid Res; 2014 Dec; 55(12):2576-86. PubMed ID: 25278499
[TBL] [Abstract][Full Text] [Related]
9. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
10. Effect of Cytochrome P450 7A1 (CYP7A1) Polymorphism on Lipid Responses to Simvastatin Treatment.
Liu N; Yang G; Liu Y; Hu M; Cai Y; Hu Z; Jia C; Zhang M
J Cardiovasc Pharmacol; 2020 Feb; 75(2):168-173. PubMed ID: 31663874
[TBL] [Abstract][Full Text] [Related]
11. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
Rosales A; Alvear M; Cuevas A; Saavedra N; Zambrano T; Salazar LA
Clin Chim Acta; 2012 Feb; 413(3-4):495-501. PubMed ID: 22120734
[TBL] [Abstract][Full Text] [Related]
12. How the cytochrome 7a1 (CYP7A1) and ATP-binding cassette G8 (ABCG8) genetic variants affect atorvastatin response among type 2 diabetic patients attending the University of Jordan Hospital.
Abed E; Jarrar Y; Alhawari H; Abdullah S; Zihlif M
Int J Clin Pharmacol Ther; 2021 Feb; 59(2):99-108. PubMed ID: 33074092
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
Kivistö KT; Niemi M; Schaeffeler E; Pitkälä K; Tilvis R; Fromm MF; Schwab M; Eichelbaum M; Strandberg T
Pharmacogenetics; 2004 Aug; 14(8):523-5. PubMed ID: 15284534
[TBL] [Abstract][Full Text] [Related]
14. Cholesteryl ester transfer protein and ATP-binding cassette transporter A1 genotype alter the atorvastatin and simvastatin efficacy: time for genotype-guided therapy?
Kolovou G; Kolovou V; Mihas C; Giannakopoulou V; Vasiliadis I; Boussoula E; Kollia A; Boutsikou M; Katsiki N; Mavrogeni S
Angiology; 2013 May; 64(4):266-72. PubMed ID: 22584245
[TBL] [Abstract][Full Text] [Related]
15. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
16. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Li YP; Zhang LR; Jia M; Hu XJ
J Clin Pharmacol; 2011 Feb; 51(2):181-8. PubMed ID: 20519697
[TBL] [Abstract][Full Text] [Related]
17. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
Wei KK; Zhang LR
Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
[TBL] [Abstract][Full Text] [Related]
18. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.
Willrich MA; Hirata MH; Genvigir FD; Arazi SS; Rebecchi IM; Rodrigues AC; Bernik MM; Dorea EL; Bertolami MC; Faludi AA; Hirata RD
Clin Chim Acta; 2008 Dec; 398(1-2):15-20. PubMed ID: 18727922
[TBL] [Abstract][Full Text] [Related]
19. The effect of leptin promoter and leptin receptor gene polymorphisms on lipid profile among the diabetic population: modulations by atorvastatin treatment and environmental factors.
Al-Azzam SI; Khabour OF; Alzoubi KH; Alzayadeen RN
J Endocrinol Invest; 2014 Sep; 37(9):835-42. PubMed ID: 24957168
[TBL] [Abstract][Full Text] [Related]
20. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
